<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minocycline (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minocycline (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Minocycline (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="122965" href="/d/html/122965.html" rel="external">see "Minocycline (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="123042" href="/d/html/123042.html" rel="external">see "Minocycline (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53763514"><span class="drugH1">Brand Names: US</span>
<ul>
<li>CoreMino [DSC];</li>
<li>Minocin;</li>
<li>Minolira;</li>
<li>Solodyn;</li>
<li>Ximino</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53763653"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>CO Minocycline;</li>
<li>TEVA-Minocycline [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F53763939"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Tetracycline Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F53763569"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Children &gt;8 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Immediate-release formulations: Initial: 4 mg/kg once (maximum dose: 200 mg), then 2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Initial: 4 mg/kg once (maximum dose: 200 mg), then 2 mg/kg/dose (maximum dose: 100 mg/dose) every 12 hours; maximum daily dose: 400 mg/<b>day</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="326e3eb0-5ca7-4fd8-913e-626158d2c2f3">Acne vulgaris, inflammatory, non-nodular, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, non-nodular, moderate to severe:</b>
<b>Note: </b>Higher doses do not confer greater efficacy and may be associated with more acute vestibular side effects. Due to emerging resistance patterns, should not typically be used as monotherapy for the management of acne vulgaris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-23637225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release formulations: Children ≥8 years and Adolescents: Oral: 50 to 100 mg 1 to 2 times daily in conjunction with topical therapy (eg, benzoyl peroxide); duration of 4 to 8 weeks of therapy usually necessary to evaluate initial clinical response with a longer duration for a maximum effect (3 to 6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release formulations: Children ≥12 years and Adolescents: Oral: ~1 mg/kg/dose once daily for 12 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Product-specific dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Extended-release capsule: Ximino: Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">45 to 59 kg: 45 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">60 to 90 kg: 90 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">91 to 136 kg: 135 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Extended-release tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">Minolira: Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">45 to 59 kg: 52.5 mg (one-half of the 105 mg tablet) once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">60 to 89 kg: 67.5 mg (one-half of the 135 mg tablet) once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">90 to 125 kg: 105 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">126 to 136 kg: 135 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">CoreMino, Solodyn: Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">45 to 49 kg: 45 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">50 to 59 kg: 55 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">60 to 71 kg: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">72 to 84 kg: 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">85 to 96 kg: 90 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">97 to 110 kg: 105 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">111 to 125 kg: 115 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">126 to 136 kg: 135 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb9edca8-3c02-4cc0-81d3-2f9dcfe8cc2f">Skin and soft tissue infection, community-acquired MRSA</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (ie, purulent cellulitis), community-acquired MRSA: Note:</b> Treatment duration based on clinical response; usual duration is 5 to 10 days for outpatient cellulitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;8 years and Adolescents: Immediate-release formulations: Oral: Initial: 4 mg/kg (maximum dose: 200 mg), then 2 mg/kg/dose (maximum dose: 100 mg/dose) every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53763498"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: IV, Oral: There are no pediatric-specific recommendations; based on experience in adult patients; dosing adjustment suggested. Hemodialysis: Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1173232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1173232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release formulations: Children ≥12 years and Adolescents: There are no specific dosage adjustments provided in the manufacturer's labeling. Consider decreasing dose or increasing dosing interval.</p></div>
<div class="block dohp drugH1Div" id="F53763496"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatotoxicity has been reported. Use with caution.</p></div>
<div class="block doa drugH1Div" id="F53763568"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="122965" href="/d/html/122965.html" rel="external">see "Minocycline (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 200 mg once, followed by 100 mg every 12 hours (maximum: 400 mg daily). For multidrug-resistant gram-negative infections (eg, carbapenem-resistant <i>Acinetobacter</i> sp., <i>S. maltophilia</i>) and nocardiosis, some experts recommend 200 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817024','lexi-content-ref-Tamma.1','lexi-content-ref-25371515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817024','lexi-content-ref-Tamma.1','lexi-content-ref-25371515'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83e0ebe8-b935-4f5a-a26d-c059d314bdfc">
<i>Acinetobacter baumannii</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Acinetobacter baumannii</i> infection, multidrug-resistant: IV, Oral: </b>200 mg every 12 hours. For mild infection, may use as monotherapy; for moderate to severe infection, administer as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tamma.1','lexi-content-ref-25371515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tamma.1','lexi-content-ref-25371515'])">Ref</a></span>). <b> Note:</b> Not recommended for urinary tract infection or as monotherapy for bloodstream infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tamma.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tamma.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c4354e0-2178-427d-a042-9beb609e2523">Acne vulgaris, inflammatory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with topical acne therapy. Some experts prefer other tetracyclines because of adverse effect profiles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Graber.1'])">Ref</a></span>). Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">IR capsule or tablet: 50 to 100 mg once or twice daily; usual dose: 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ER capsule or tablet: 1 mg/kg once daily, rounded to the nearest dosage form available; maximum dose: 135 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">ER capsule:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Ximino:</i></p>
<p style="text-indent:-2em;margin-left:12em;">45 to 59 kg: 45 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">60 to 90 kg: 90 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">91 to 136 kg: 135 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">ER tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Minolira:</i></p>
<p style="text-indent:-2em;margin-left:12em;">45 to 59 kg: 52.5 mg (one-half of the 105 mg tablet) once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">60 to 89 kg: 67.5 mg (one-half of the 135 mg tablet) once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">90 to 125 kg: 105 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">126 to 136 kg: 135 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>CoreMino, Solodyn:</i></p>
<p style="text-indent:-2em;margin-left:12em;">45 to 49 kg: 45 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">50 to 59 kg: 55 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">60 to 71 kg: 65 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">72 to 84 kg: 80 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">85 to 96 kg: 90 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">97 to 110 kg: 105 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">111 to 125 kg: 115 mg once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">126 to 136 kg: 135 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e8820e5-cd13-4b2d-840c-74174ab30524">Leprosy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leprosy (alternative agent) (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lepromatous (multibacillary): </i>100 mg once daily for 24 months as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HRSA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HRSA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tuberculoid (paucibacillary):</i> 100 mg once daily for 12 months in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HRSA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HRSA.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee503525-0e5d-4809-a500-384b58e44e0a">Meningococcal disease, chemoprophylaxis after close contact with a patient with invasive disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal </b>
<b>disease, chemoprophylaxis after close contact with a patient with invasive disease: Note:</b> CDC recommendations do not mention use of minocycline for eradicating nasopharyngeal carriage of meningococcus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McNamara.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McNamara.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 100 mg every 12 hours for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7559f7b6-efbf-4f9f-9141-22a6d7dd3c57">
<i>Mycobacterium marinum</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium marinum:</i></b>
<b>Oral:</b> 100 mg every 12 hours for 2 to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24002023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24002023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1e4676d-acfb-4622-bd32-467372cbc36c">Nocardiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nocardiosis (alternative agent) (off-label use):</b>
<b>IV,</b>
<b>Oral:</b> 100 to 200 mg every 12 hours, generally as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30817024','lexi-content-ref-33418019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30817024','lexi-content-ref-33418019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague </b>
<i>
<b>(Yersinia pestis</b></i>
<b>) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis:</i>
<b>Oral:</b> 100 mg every 12 hours for 7 days; a 200 mg loading dose is recommended in patients who are pregnant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, bubonic or pharyngeal</i>: <b>Oral, IV:</b> 200 mg initially then 100 mg every 12 hours for 10 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: Oral continuation therapy for Staphylococcus (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis): </i>
<b>Oral: </b>100 mg twice daily in combination with rifampin; duration is ≥3 months, depending on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic suppression for staphylococci (methicillin-resistant) and Cutibacterium acnes (alternative agent for C. acnes):</i>
<b>Oral:</b> 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rheumatoid arthritis (off-label use):</b>
<b>Oral:</b> 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8185689','lexi-content-ref-9153544','lexi-content-ref-11665963','lexi-content-ref-14528503','lexi-content-ref-7993000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8185689','lexi-content-ref-9153544','lexi-content-ref-11665963','lexi-content-ref-14528503','lexi-content-ref-7993000'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chlamydial or </i>
<i>Ureaplasma urealyticum </i>
<i>infection, uncomplicated:</i>
<b>Note:</b> Clinical practice guidelines do not mention use of minocycline for treatment of chlamydial or <i>U. urealyticum</i> infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> Urethral, endocervical, or rectal: 100 mg every 12 hours for at least 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal infection, uncomplicated (males): </i>
<b>Note:</b> Clinical practice guidelines do not recommend tetracyclines for the treatment of gonorrhea because of increased resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Urethritis:</i> Oral, IV:</b> 100 mg every 12 hours for 5 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Without urethritis or anorectal infection:</i> Oral, IV:</b> 200 mg once, followed by 100 mg every 12 hours for at least 4 days (cultures 2 to 3 days post therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Syphilis (alternative agent for nonpregnant patients with penicillin allergy):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Limited data support use of minocycline as an alternative to penicillin, and close serologic and clinical follow-up is warranted; some experts prefer other alternative agents (eg, ceftriaxone, doxycycline) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Hicks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Hicks.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Early syphilis (primary, secondary, and early latent [&lt;1-year duration]):</i>
<b> Oral, IV:</b> 200 mg once followed by 100 mg every 12 hours for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28033297','lexi-content-ref-33496202','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28033297','lexi-content-ref-33496202','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, nonpurulent with risk for methicillin-resistant <i>S. aureus:</i></b>
<b>Oral: </b>100 mg twice daily in combination with an additional agent (eg, amoxicillin, cephalexin) for coverage of beta-hemolytic streptococci (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>). Some experts give an initial 200 mg loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, purulent or abscess:</b>
<b>Oral: </b>100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>). Some experts give an initial 200 mg loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spelman.1'])">Ref</a></span>). <b>Note</b>: Systemic antibiotics only indicated for abscess in certain instances (eg, immunocompromised patients, signs of systemic infection, large or multiple abscesses, indwelling device, high risk for adverse outcome with endocarditis). If at risk for gram-negative bacilli, use in combination with an appropriate agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dc8c99e-5200-48dc-a3c4-2ab11d9c2d8d">
<i>Stenotrophomonas maltophilia</i> infection, multidrug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Stenotrophomonas maltophilia</i> infection, multidrug-resistant (alternative agent) (off-label use): IV, Oral: </b>200 mg every 12 hours. For mild infection, may use as monotherapy; for moderate to severe infection, administer as part of an appropriate combination regimen. <b>Note:</b> Not recommended for urinary tract infection or as monotherapy for bloodstream infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tamma.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tamma.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53763497"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4459000','lexi-content-ref-28357705','lexi-content-ref-1211910']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4459000','lexi-content-ref-28357705','lexi-content-ref-1211910'])">Ref</a></span>). <b>Note:</b> Theoretically, minocycline doses &gt;200 mg/day may increase plasma urea concentrations due to antianabolic effects. Therefore, patients with kidney impairment requiring doses &gt;200 mg/day should be frequently monitored for increased BUN, serum creatinine, and/or signs and symptoms of uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28357705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28357705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4459000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4459000'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1211910','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1211910','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4459000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4459000'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: <b>Oral, IV:</b></b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): <b>Oral, IV:</b></b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F53763495"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, hepatotoxicity has been reported. Use with caution.</p></div>
<div class="block arsc drugH1Div" id="F57426561"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone growth suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bone growth suppression, as evidenced by growth retardation (fibula), has been reported in premature infants treated with tetracycline; growth restriction up to 40% has been associated with oral tetracycline therapy but is reversible when short-term treatment is discontinued. Upon discontinuation of tetracycline, rapid compensatory bone growth is observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14074423','lexi-content-ref-30442509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14074423','lexi-content-ref-30442509'])">Ref</a></span>). There are limited/no data with minocycline; therefore, the risk for bone growth suppression is extrapolated from data with tetracycline.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; tetracycline binds to calcium in growing bones and negatively affects calcium orthophosphate metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14074423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14074423'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; deposition of tetracycline in bone has been shown after one dose and treatment with tetracycline for 9 to 12 days has resulted in restricted bone growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14074423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14074423'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; tetracycline 25 mg/kg/dose every 6 hours in premature infants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14074423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14074423'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age: Premature infants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14074423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14074423'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Minocycline is associated with <b>dizziness, tinnitus, </b>and <b>vertigo</b>, which are often mild and reversible within 48 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-788583','lexi-content-ref-324400','lexi-content-ref-23441623','lexi-content-ref-303498','lexi-content-ref-1081373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-788583','lexi-content-ref-324400','lexi-content-ref-23441623','lexi-content-ref-303498','lexi-content-ref-1081373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; readily crosses the blood-brain barrier, impacts microglia activation and cytokine expression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23441623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23441623'])">Ref</a></span>). Peak minocycline serum concentrations correlate with the peak onset of adverse reactions; however, lower doses do not appear to improve adverse reaction profile with short treatment courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-324400','lexi-content-ref-303498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-324400','lexi-content-ref-303498'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Onset</i>: Rapid; usually within 2 to 3 days of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-324400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-324400'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Idiopathic intracranial hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Idiopathic <b>intracranial hypertension</b> (ie, pseudotumor cerebri) has been associated with minocycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31741184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31741184'])">Ref</a></span>). Symptoms include headache (predominant symptom), blurred vision, diplopia, vision loss, and/or papilledema. Intracranial hypertension is typically benign and resolves with discontinuation; however, permanent vision loss is possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22490325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22490325'])">Ref</a></span>). Intracranial pressure may remain elevated for 2 to 5 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22490325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22490325'])">Ref</a></span>). Idiopathic intracranial hypertension has been reported in infants following tetracycline exposure, manifested by <b>bulging fontanel</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-13699377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-13699377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; proposed that minocycline reduces cerebrospinal fluid absorption at the arachnoid villi, leading to increased intracranial pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9683157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9683157'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; generally within 8 weeks of initiation (range &lt;1 week to 1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9683157','lexi-content-ref-15675888','lexi-content-ref-31741184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9683157','lexi-content-ref-15675888','lexi-content-ref-31741184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent isotretinoin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15675888']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15675888'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females of childbearing age (especially those who are overweight, obese, have experienced recent weight gain, or have a history of intracranial hypertension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12038730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12038730'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Minocycline may cause <b>hepatotoxicity</b> (ranging from mild elevations in serum aminotransferase levels to <b>hepatic failure </b>[including fatal cases]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-26782675','lexi-content-ref-1532250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-26782675','lexi-content-ref-1532250'])">Ref</a></span>). Liver injury may present as an acute <b>hepatitis</b>-like syndrome, or a chronic <b>autoimmune hepatitis</b>, usually with hepatocellular pattern of enzyme elevation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-1532250','lexi-content-ref-11504273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-1532250','lexi-content-ref-11504273'])">Ref</a></span>). Autoantibodies are usually present with autoimmune hepatitis, typically antinuclear antibody (ANA) at titers of &gt;1:160 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12583618','lexi-content-ref-18617786','lexi-content-ref-30186098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12583618','lexi-content-ref-18617786','lexi-content-ref-30186098'])">Ref</a></span>). Most cases of hepatotoxicity resolve within 3 months after discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-1532250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617786','lexi-content-ref-30345250','lexi-content-ref-1532250'])">Ref</a></span>). Some cases may require treatment; persistent and severe injury has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30345250','lexi-content-ref-1532250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30345250','lexi-content-ref-1532250'])">Ref</a></span>). Hepatic failure is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26782675','lexi-content-ref-1532250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26782675','lexi-content-ref-1532250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; not clearly established, immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30345250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30345250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; acute hepatitis: 3 to 4 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617786','lexi-content-ref-1532250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617786','lexi-content-ref-1532250'])">Ref</a></span>). Autoimmune hepatitis: generally occurs with prolonged therapy (average within 2 years but may occur within a few months after initiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18617786','lexi-content-ref-30345250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18617786','lexi-content-ref-30345250'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• First month of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11504273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11504273'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed) and autoimmune syndromes</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions include immediate (eg, <b>anaphylaxis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20676339','lexi-content-ref-8740283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20676339','lexi-content-ref-8740283'])">Ref</a></span>) and delayed reactions. <b>Drug reaction with eosinophilia and systemic symptoms </b>(DRESS) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19153346','lexi-content-ref-18182810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19153346','lexi-content-ref-18182810'])">Ref</a></span>). Although the liver is the main organ affected, <b>meningitis</b>, <b>myocarditis</b>, and <b>pneumonitis</b> may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7787604','lexi-content-ref-19153346','lexi-content-ref-24471460','lexi-content-ref-17511865','lexi-content-ref-30775664','lexi-content-ref-12796202','lexi-content-ref-35160164','lexi-content-ref-8031212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7787604','lexi-content-ref-19153346','lexi-content-ref-24471460','lexi-content-ref-17511865','lexi-content-ref-30775664','lexi-content-ref-12796202','lexi-content-ref-35160164','lexi-content-ref-8031212'])">Ref</a></span>). DRESS may have a prolonged course with development of autoimmune syndromes, including <b>diabetes mellitus</b>, <b>hepatitis</b>, <b>thyroiditis</b>, and <b>vasculitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24979843','lexi-content-ref-19153345','lexi-content-ref-10406406','lexi-content-ref-30345250','lexi-content-ref-26782675','lexi-content-ref-31533103','lexi-content-ref-32730650','lexi-content-ref-19665822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24979843','lexi-content-ref-19153345','lexi-content-ref-10406406','lexi-content-ref-30345250','lexi-content-ref-26782675','lexi-content-ref-31533103','lexi-content-ref-32730650','lexi-content-ref-19665822'])">Ref</a></span>). Other cutaneous reactions that have been associated with minocycline include <b>serum sickness-like reaction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18432045','lexi-content-ref-8740328','lexi-content-ref-8712844','lexi-content-ref-10877258','lexi-content-ref-34449992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18432045','lexi-content-ref-8740328','lexi-content-ref-8712844','lexi-content-ref-10877258','lexi-content-ref-34449992'])">Ref</a></span>), <b>Stevens-Johnson syndrome/toxic epidermal necrolysis</b> (SJS/TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30402608','lexi-content-ref-21103193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30402608','lexi-content-ref-21103193'])">Ref</a></span>), <b>Sweet syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23158645','lexi-content-ref-12207601','lexi-content-ref-32551128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23158645','lexi-content-ref-12207601','lexi-content-ref-32551128'])">Ref</a></span>), <b>fixed drug eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10447381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10447381'])">Ref</a></span>) and <b>lupus-like syndrome</b>, usually with positive ANA antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234017','lexi-content-ref-29469742','lexi-content-ref-10406406','lexi-content-ref-8563540','lexi-content-ref-11285382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234017','lexi-content-ref-29469742','lexi-content-ref-10406406','lexi-content-ref-8563540','lexi-content-ref-11285382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are IgE-mediated. Delayed hypersensitivity reactions are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>), triggered by minocycline or a reactive metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34206485','lexi-content-ref-9382560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34206485','lexi-content-ref-9382560'])">Ref</a></span>). Prolonged courses of DRESS may be the result of accumulation of melanin-minocycline complex in patients with pigmented skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182810'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; DRESS has been reported 16 to 60 days after initiation (mean 23.7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8712844','lexi-content-ref-18182810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8712844','lexi-content-ref-18182810'])">Ref</a></span>), and serum sickness-like reactions approximately 16 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8712844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8712844'])">Ref</a></span>). Lupus-like syndrome occurs from 3 months to 6 years (median 22.5 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234017','lexi-content-ref-9382560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234017','lexi-content-ref-9382560'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (for autoimmune syndromes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22895927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22895927'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• African or West Indian origin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11051220','lexi-content-ref-34206485','lexi-content-ref-18182810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11051220','lexi-content-ref-34206485','lexi-content-ref-18182810'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (for lupus-like syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234017','lexi-content-ref-8563540','lexi-content-ref-10074958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234017','lexi-content-ref-8563540','lexi-content-ref-10074958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between minocycline and other tetracyclines is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10447381','lexi-content-ref-31382572','lexi-content-ref-8031212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10447381','lexi-content-ref-31382572','lexi-content-ref-8031212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Viral reactivation, in particular human herpesvirus 6 (HHV-6) has been associated with DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12839588','lexi-content-ref-34206485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12839588','lexi-content-ref-34206485'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased risk with minocycline for DRESS and autoimmune syndromes compared to other tetracyclines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22283782','lexi-content-ref-9382560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22283782','lexi-content-ref-9382560'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants (for lupus-like syndrome) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10735951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10735951'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Photosensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Minocycline may cause <b>skin photosensitivity</b> reactions ranging from mild sunburn-like reactions to photodermatitis. However, minocycline is less phototoxic than other tetracyclines (eg, doxycycline) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5026677','lexi-content-ref-33991382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5026677','lexi-content-ref-33991382'])">Ref</a></span>). Reactions have not been reported with topical minocycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31179779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31179779'])">Ref</a></span>). Phototoxic reactions are restricted to exposed skin, usually develop shortly after sun exposure, and appear to be dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9778198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9778198'])">Ref</a></span>). Photo-<b>onycholysis</b> has also been reported, which may take up to 6 months to resolve after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6455257','lexi-content-ref-30933349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6455257','lexi-content-ref-30933349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; minocycline absorbs light energy resulting in subsequent photochemical reactions in living tissues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33991382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33991382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; photosensitivity occurs &lt;24 hours after sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888626'])">Ref</a></span>). Photo-onycholysis may occur weeks after sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6455257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6455257'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Skin hyperpigmentation/dental discoloration</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Minocycline may induce diffuse <b>skin hyperpigmentation</b> (brown, bluish-grey, and/or black discoloration) including nails, skin of face, arms, legs, or around scars and dental discoloration (<b>staining of tooth</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19595269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19595269'])">Ref</a></span>). Hyperpigmentation may be more prevalent with minocycline than doxycycline and associated with a greater variety of tissues (eg, bone, conjunctiva and sclera, ear tympanic membrane, internal organs, nails, subcutaneous fat, teeth and oral mucosa, and thyroid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20720371','lexi-content-ref-11896769','lexi-content-ref-27870777','lexi-content-ref-23887527','lexi-content-ref-8436641','lexi-content-ref-32839167','lexi-content-ref-34348742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20720371','lexi-content-ref-11896769','lexi-content-ref-27870777','lexi-content-ref-23887527','lexi-content-ref-8436641','lexi-content-ref-32839167','lexi-content-ref-34348742'])">Ref</a></span>). Minocycline hyperpigmentation and dental discoloration may be partially reversible, but permanent in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33494681','lexi-content-ref-34206485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33494681','lexi-content-ref-34206485'])">Ref</a></span>). Discoloration may be amenable to vital bleaching (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23887527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23887527'])">Ref</a></span>). Minocycline may affect fully erupted teeth compared to tetracycline, which may cause dental staining and <b>enamel hypoplasia</b> in unerupted, uncalcified teeth. Furthermore, the gingival third of the crown tends to be spared in minocycline staining compared with tetracycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23887527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23887527'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; minocycline may mineralize tissue as it binds to calcium/iron to form a tetracycline-calcium/iron orthophosphate complex and/or activate melanocytes in the upper dermis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12716217','lexi-content-ref-33916535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12716217','lexi-content-ref-33916535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; months to years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2584464','lexi-content-ref-9029456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2584464','lexi-content-ref-9029456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (≥100 mg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2584464','lexi-content-ref-9029456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2584464','lexi-content-ref-9029456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use (&gt;1 to 2 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2584464','lexi-content-ref-9029456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2584464','lexi-content-ref-9029456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sun-exposed areas of skin with higher density of melanocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34919357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34919357'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F53763539"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (5%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (9%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (2%), fatigue (9%), malaise (4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Minocycline (Systemic): Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Minocycline [Systemic])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Minocycline [Systemic])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">674</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (2%)<span class="lexi-table-link-container"> (<a aria-label="Tinnitus table link" class="lexi-table-link" data-table-id="lexi-content-tinnitus" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tinnitus')">table 2</a>)</span><span class="table-link" style="display:none;">Tinnitus</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tinnitus" frame="border" id="lexi-content-tinnitus" rules="all">
<caption style="text-align:center;">
<b>Minocycline (Systemic): Adverse Reaction: Tinnitus</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Minocycline [Systemic])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Minocycline [Systemic])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">674</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">364</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis (Shaughnessy 2010), pericarditis (Davey 2000), vasculitis (including polyarteritis nodosa [Agur 2014])</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (Knowles 1996), exfoliative dermatitis (Davies 1989), fixed drug eruption (Correia 1999), onycholysis (McCarthy 2019), skin hyperpigmentation (Rok 2021, Wang 2021), skin photosensitivity (Odorici 2021), skin pigmentation (Shute 2020), skin rash, Stevens-Johnson syndrome (Yoon 2010), Sweet syndrome (Khanna 2020), toxic epidermal necrolysis (Dominic 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal thyroid function test (Millington 2019), diabetes mellitus (Brown 2009), malignant neoplasm of thyroid (Kandil 2010), microscopic thyroid discoloration (Azuma 2010, Kandil 2010), thyroiditis (Millington 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis, <i>Clostridioides difficile</i>-associated diarrhea, diarrhea, dysphagia, enamel hypoplasia, enterocolitis, glossitis, mucous membrane hyperpigmentation (Eisen 1998), pancreatitis (Shapiro 1997), parotitis (bilateral) (Yoon 2010), staining of tooth (Johnston 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Balanitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia (Kudoh 1994), Henoch-Schonlein purpura, lymphadenopathy (Bando 1994), thrombocytopenia (Dominic 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Harmon 2018), hepatic failure (Lan 2016), hepatitis, hepatotoxicity (Chalasani 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Jang 2010), angioedema (Jang 2010), drug reaction with eosinophilia and systemic symptoms (Eshki 2009), nonimmune anaphylaxis (Okana 1996), serum sickness (Elkayam 1999), serum sickness-like reaction (Lucido 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Bulging fontanel (Fields 1961), intracranial hypertension (Tan 2019), meningitis (Lefebvre 2007), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, exacerbation of systemic lupus erythematosus (Elkayam 1999), joint stiffness, joint swelling, lupus-like syndrome (Clark 2017), myalgia, polyarthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss, vestibular ototoxicity (Jacobson 1975<span style="text-decoration: underline">)</span></p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Dominic 2021), nephritis (including acute intestinal nephritis [Sharma 2020])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (including eosinophilic pneumonitis [Dykhuizen 1995]), pulmonary infiltrates (Dykhuizen 1995), respiratory failure (Oddo 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F53763536"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to minocycline, other tetracyclines, or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe liver disease; complete renal failure; myasthenia gravis; use in children &lt;13 years of age; pregnancy; breastfeeding</p></div>
<div class="block war drugH1Div" id="F53763537"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or in conjunction with other hepatotoxic drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with kidney impairment. see "Dosing: Altered Kidney Function" for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May cause tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration; more common with long-term use, but observed with repeated, short courses; use of tetracyclines should be avoided during tooth development (infancy and children ≤8 years of age) unless other drugs are not likely to be effective or are contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Magnesium content: Parenteral (IV) formulation contains magnesium; monitor serum magnesium in patients with renal impairment and signs of magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression leading to respiratory paralysis). Also use with caution and closely monitor patients with heart block or myocardial damage.</p></div>
<div class="block dosfc drugH1Div" id="F53763585"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Minocin Kit contains minocycline oral capsules packaged with T3 Calming Wipes</p>
<p style="text-indent:-2em;margin-left:2em;">Minocin for injection contains magnesium 2.2 mEq per vial</p></div>
<div class="block foc drugH1Div" id="F53763583"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minocin: 50 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 75 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ximino: 90 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ximino: 135 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ximino: 45 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 135 mg, 45 mg, 90 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minocin: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 75 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CoreMino: 45 mg [DSC], 90 mg [DSC], 135 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minolira: 105 mg, 135 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solodyn: 55 mg [contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solodyn: 65 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solodyn: 80 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solodyn: 105 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solodyn: 115 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigotine,indigo carmine), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, 135 mg</p></div>
<div class="block geq drugH1Div" id="F53763517"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F53763587"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Minocycline HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $21.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $21.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">135 mg (per each): $21.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Ximino Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $33.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $33.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">135 mg (per each): $33.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Minocycline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $1.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.38 - $3.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Minocin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $301.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Minocycline HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">45 mg (per each): $20.17 - $24.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">55 mg (per each): $39.01 - $43.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg (per each): $39.01 - $43.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $39.01 - $43.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $20.17 - $24.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg (per each): $39.01 - $43.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">115 mg (per each): $39.01 - $43.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">135 mg (per each): $20.17 - $24.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Minolira Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg (per each): $29.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">135 mg (per each): $29.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Solodyn Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">55 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">65 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">105 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">115 mg (per each): $2.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Minocycline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $3.43 - $4.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $5.04 - $6.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53763654"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F53763493"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 60 minutes; avoid rapid administration; the injectable route should be used only if the oral route is not feasible or adequate; prolonged intravenous therapy may be associated with thrombophlebitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with plenty of fluids with or without food. Ingestion of adequate amounts of fluid and food may reduce the risk of esophageal irritation and ulceration. Swallow pellet-filled capsule and extended-release tablet whole; do not chew, crush, or split. Minolira 105 mg and 135 mg extended-release tablets may be split on the score line. Administer antacids, calcium supplements, iron supplements, magnesium-containing laxatives, and cholestyramine 2 hours before or after minocycline.</p></div>
<div class="block adm drugH1Div" id="F53763571"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 60 minutes; avoid rapid administration. The injectable route should be used only if the oral route is not feasible or adequate. Prolonged intravenous therapy may be associated with thrombophlebitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food. Administer with adequate fluid to decrease the risk of esophageal irritation and ulceration. Swallow pellet-filled capsule and ER tablet or capsule whole; do not chew, crush, or split. Minolira 105 mg and 135 mg ER tablets may be split on the score line.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsule (Ximino) and tablet (CoreMino, Solodyn) should be swallowed whole. Do not chew, crush, or split. ER tablet (Minolira) may be split on the score line. IR tablet, capsule, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, consideration should be given to conversion to IR formulations for high-risk labeled and off-label indications.</p></div>
<div class="block sts drugH1Div" id="F53763553"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule (including pellet-filled), tablet: Store at 20°C to 25°C (68°F to 77°F); protect from heat, light, and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release capsule: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Protect from light, moisture, and excessive heat.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release tablet: Store at 15°C to 30°C (59°F to 86°F); protect from heat, light, and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials at 20°C to 25°C (68°F to 77°F). Diluted solution in NS, D5W, D5NS, or LR is stable at room temperature for up to 4 hours or at 2°C to 8°C (36°F to 46°F) for up to 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53763659"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Injection, immediate-release oral tablet, capsules, and oral suspension: Treatment of susceptible gram-negative infections (eg, <i>Acinetobacter</i> spp, <i>Escherichia coli</i>, <i>Enterobacter aerogenes</i>, <i>Shigella</i> spp) including infections of the respiratory tract (ie, <i>Haemophilus influenzae</i>, <i>Klebsiella</i> spp, or <i>Mycoplasma pneumoniae)</i> and urinary tract (ie, <i>Klebsiella</i> spp) and gram-positive infections including upper respiratory tract infections caused by <i>Streptococcus pneumoniae </i>and skin and skin structure infections caused by <i>Staphylococcus aureus </i>(not considered a first-line agent for any staphylococcal infection); treatment of rickettsial diseases (including Rocky Mountain spotted fever, typhus fever, Q fever), chlamydial infections, psittacosis (ornithosis) due to <i>Chlamydophila psittaci</i>, relapsing fever caused by <i>Borrelia recurrentis</i>, plague due to<i> Yersinia pestis</i>, cholera caused by <i>Vibrio cholerae</i>, infections caused by <i>Campylobacter fetus</i>, tularemia due to <i>Francisella tularensis,</i> brucellosis due to <i>Brucella</i> species (in conjunction with streptomycin), and bartonellosis due to <i>Bartonella bacilliformis;</i> treatment of chancroid caused by <i>Haemophilus ducreyi </i>(Oral formulations only); treatment to eliminate the meningococci from the nasopharynx of asymptomatic carriers of <i>Neisseria</i>
<i> meningitidis</i> (Oral formulations only); adjunct treatment for acute intestinal amebiasis and severe acne; alternative treatment (when penicillin is contraindicated) for syphilis, yaws, listeriosis, anthrax, Vincent infection, actinomycosis, and infections caused by<i> Clostridium </i>species; alternative treatment (when penicillin is contraindicated) of meningitis due to <i>N. meningitidis</i> (IV only) (All indications: FDA approved in ages &gt;8 years and adults); treatment of nongonococcal urethritis, endocervical, or rectal infections caused by <i>Ureaplasma urealyticum</i> or <i>Chlamydia trachomatis </i> (FDA approved in adults); alternative treatment (when penicillin is contraindicated) for gonorrhea infections (Oral formulations only) (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release capsules and tablets: Treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris (FDA approved in ages ≥12 years and adults)</p></div>
<div class="block mst drugH1Div" id="F53763509"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dynacin may be confused with Dyazide, Dynapen</p>
<p style="text-indent:-2em;margin-left:4em;">Minocin may be confused with Indocin, Lincocin, Minizide, niacin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53763546"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53763543"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Minocycline (Systemic) may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: Minocycline (Systemic) may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Tetracyclines may decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines.  Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Tetracyclines may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. If coadministration cannot be avoided, administer the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the tetracycline derivative. Monitor for decreased tetracycline effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines cannot be avoided, administer the polyvalent cation-containing multivitamin either 2 hours before or 4 hours after the tetracycline product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Minocycline (Systemic) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Tetracyclines. Management: Give oral tetracyclines at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinapril: May decrease the serum concentration of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 hour before sucroferric oxyhydroxide. Specific dose separation guidelines for other tetracyclines are not presently available. No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hours to minimize this interaction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F53763551"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Minocycline serum concentrations are not significantly altered if taken with food or dairy products. Management: Administer without regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F53763532"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Minocycline is excreted in seminal fluid (Saivin 1988). Minocycline is not recommended for the treatment of acne in males or females attempting to conceive a child.</p></div>
<div class="block pri drugH1Div" id="F53763531"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Minocycline crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Tetracycline-class antibiotics may cause fetal harm following maternal use in pregnancy. Rare spontaneous reports of congenital anomalies, including limb reduction, have been reported following maternal minocycline use. Due to limited information, a causal association cannot be established. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>
<p style="text-indent:0em;margin-top:2em;">As a class, tetracyclines are generally considered second-line antibiotics in pregnant patients and their use should be avoided (Mylonas 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Yersinia pestis</i>) infection in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis; </i>parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Minocycline may be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis </i>(CDC [Nelson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Minocycline is not recommended for the treatment of Rocky Mountain Spotted Fever (Biggs 2016), Q fever (Anderson 2012), or anthrax infection (Meaney-Delman 2014) in pregnant patients. Agents other than minocycline are recommended when systemic antibiotics are needed to treat acne during pregnancy (AAD [Zaenglein 2016]).</p></div>
<div class="block mopp drugH1Div" id="F53763660"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">All products: CBC, serum BUN, creatinine, liver function tests. Observe for changes in bowel frequency. Periodically examine face, trunk, legs, oral mucosa, sclera, and nail beds for hyperpigmentation (Eichenfield 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Monitor magnesium concentrations in patients with renal impairment.</p></div>
<div class="block pha drugH1Div" id="F53763558"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not affected.</p></div>
<div class="block phk drugH1Div" id="F53763559"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed to most body fluids, bile, and tissues; poor CNS penetration; deposits in fat for extended periods; V<sub>d</sub>: 0.14 to 0.7 L/kg (Zhanel 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 55% to 96% (Zhanel 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 90% to 100% (Zhanel 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 15 to 23 hours; 11 to 16 hours (hepatic impairment); 18 to 69 hours (renal impairment); Oral: 16 hours (range: 11 to 17 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Capsule, pellet filled: 1 to 4 hours; Tablet: 1 to 3 hours; Extended release tablet: 3.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (5% to 12% excreted unchanged) (Brogden 1975; Zhanel 2004); feces (20% to 34%) (Brogden 1975)</p></div>
<div class="block phksp drugH1Div" id="F56100291"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time and concentration dependent, associated with free 24-hour area under the curve (<i>f</i>AUC<sub>24</sub>)/minimum inhibitory concentration (MIC) (Agwuh 2006; Ambrose 2007; Cunha 2000; Lashinsky 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acinetobacter baumannii:</i>
<i>f</i>AUC<sub>24</sub>/MIC goal: ≥20 to 25 (1-log kill) (Alfouzan 2017; Tarazi 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AUC:</p>
<p style="text-indent:-2em;margin-left:8em;">Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Oral:</p>
<p style="text-indent:-2em;margin-left:12em;">100 mg single dose: AUC<sub>0-11</sub>: 9.64 ± 3.73 mg•hour/L (range: 3.8 to 19 mg•hour/L) (Maesen 1989).</p>
<p style="text-indent:-2em;margin-left:12em;">200 mg, single dose: AUC<sub>0-24</sub>: ~47 mg•hour/L (Cartwright 1975).</p>
<p style="text-indent:-2em;margin-left:10em;">IV:</p>
<p style="text-indent:-2em;margin-left:12em;">200 mg, single dose: AUC<sub>0-7</sub>: 67 mg•hour/L (Agwuh 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> ~2 to 3 hours (<i>B. anthracis</i>) (Athamna 2004).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58846821"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Menocik</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12583618">
<a name="12583618"></a>Abe M, Furukawa S, Takayama S, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. <i>Intern Med</i>. 2003;42(1):48-52. doi:10.2169/internalmedicine.42.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12583618/pubmed" id="12583618" target="_blank">12583618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24979843">
<a name="24979843"></a>Agur T, Levy Y, Plotkin E, Benchetrit S. Minocycline-induced polyarteritis nodosa-like vasculitis. <i>Isr Med Assoc J</i>. 2014;16(5):322-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24979843/pubmed" id="24979843" target="_blank">24979843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16816396">
<a name="16816396"></a>Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. <i>J Antimicrob Chemother.</i> 2006;58(2):256-265. doi:10.1093/jac/dkl224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/16816396/pubmed" id="16816396" target="_blank">16816396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28705678">
<a name="28705678"></a>Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. <i>Int J Antimicrob Agents.</i> 2017;50(6):715-717. doi:10.1016/j.ijantimicag.2017.06.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/28705678/pubmed" id="28705678" target="_blank">28705678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-788583">
<a name="788583"></a>Allen JC. Minocycline. <i>Ann Intern Med</i>. 1976;85(4):482-487. doi:10.7326/0003-4819-85-4-482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/788583/pubmed" id="788583" target="_blank">788583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17143821">
<a name="17143821"></a>Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. <i>Clin Infect Dis.</i> 2007;44(1):79-86. doi:10.1086/510079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/17143821/pubmed" id="17143821" target="_blank">17143821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109210">
<a name="23109210"></a>Anderson M, Kuzniar TJ, et al. Pulmonary nocardiosis in a patients with chronic obstructive pulmonary disease- case report and literature review. <i>Pneumonol Alergol Pol</i>. 2012;80(6):565-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23109210/pubmed" id="23109210" target="_blank">23109210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12038730">
<a name="12038730"></a>Ang ER, Zimmerman JC, Malkin E. Pseudotumor cerebri secondary to minocycline intake. <i>J Am Board Fam Pract</i>. 2002;15(3):229-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12038730/pubmed" id="12038730" target="_blank">12038730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234017">
<a name="15234017"></a>Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. <i>Clin Dermatol</i>. 2004;22(2):157-166. doi:10.1016/j.clindermatol.2003.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/15234017/pubmed" id="15234017" target="_blank">15234017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-minocycline.2018.08">
<a name="Apo-minocycline.2018.08"></a>Apo-minocycline [product monograph]. Toronto, Ontario, Canada: Apotex Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998982">
<a name="14998982"></a>Athamna A, Athamna M, Medlej B, Bast DJ, Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J Antimicrob Chemother. 2004;53(4):609-615. doi:10.1093/jac/dkh130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/14998982/pubmed" id="14998982" target="_blank">14998982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20720371">
<a name="20720371"></a>Azuma N, Hashimoto N, Nishioka A, Sano H. Black thyroid. <i>Intern Med</i>. 2010;49(16):1835-1836. doi:10.2169/internalmedicine.49.3528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/20720371/pubmed" id="20720371" target="_blank">20720371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4038862">
<a name="4038862"></a>Basler RS, Lynch PJ. Black galactorrhea as a consequence of minocycline and phenothiazine therapy. <i>Arch Dermatol</i>. 1985;121(3):417-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/4038862/pubmed" id="4038862" target="_blank">4038862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2584464">
<a name="2584464"></a>Berger RS, Mandel EB, Hayes TJ, Grimwood RR. Minocycline staining of the oral cavity. <i>J Am Acad Dermatol</i>. 1989;21(6):1300-1301. doi:10.1016/s0190-9622(89)80309-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/2584464/pubmed" id="2584464" target="_blank">2584464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18432045">
<a name="18432045"></a>Bettge AM, Gross GN. A serum sickness-like reaction to a commonly used acne drug. <i>JAAPA</i>. 2008;21(3):33-34. doi:10.1097/01720610-200803000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/18432045/pubmed" id="18432045" target="_blank">18432045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27172113">
<a name="27172113"></a>Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/27172113/pubmed" id="27172113" target="_blank">27172113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30888626">
<a name="30888626"></a>Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity-An update: Culprit drugs, prevention and management. <i>Drug Saf</i>. 2019;42(7):827-847. doi:10.1007/s40264-019-00806-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30888626/pubmed" id="30888626" target="_blank">30888626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9228128">
<a name="9228128"></a>Bluhm GB, Sharp JT, Tilley BC, et al. Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) trial. <i>J Rheumatol</i>. 1997;24(7):1295-1302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9228128/pubmed" id="9228128" target="_blank">9228128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24002023">
<a name="24002023"></a>Bonamonte D, De Vito D, Vestita M, et al. Aquarium-borne Mycobacterium marinum skin infection. Report of 15 cases and review of the literature. <i>Eur J Dermatol</i>. 2013;23(4):510-516. doi:10.1684/ejd.2013.2103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24002023/pubmed" id="24002023" target="_blank">24002023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1173232">
<a name="1173232"></a>Brogden RN, Speight TM, Avery GS. Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. <i>Drugs</i>. 1975;9(4):251-291. doi:10.2165/00003495-197509040-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1173232/pubmed" id="1173232" target="_blank">1173232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19153345">
<a name="19153345"></a>Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. <i>Arch Dermatol</i>. 2009;145(1):63-66. doi:10.1001/archdermatol.2008.521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/19153345/pubmed" id="19153345" target="_blank">19153345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4459000">
<a name="4459000"></a>Carney S, Butcher RA, Dawborn JK, Pattison G. Minocycline excretion and distribution in relation to renal function in man. <i>Clin Exp Pharmacol Physiol</i>. 1974;1(4):299-308. doi:10.1111/j.1440-1681.1974.tb00552.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/4459000/pubmed" id="4459000" target="_blank">4459000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1184503">
<a name="1184503"></a>Cartwright AC, Hatfield HL, Yeadon A, London E. A comparison of the bioavailability of minocycline capsules and film-coated tablets. <i>J Antimicrob Chemother.</i> 1975;1(3):317-322. doi:10.1093/jac/1.3.317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1184503/pubmed" id="1184503" target="_blank">1184503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966. doi:10.1038/ajg.2014.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28714183">
<a name="28714183"></a>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2018;67(1):328-357. doi:10.1002/hep.29367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/28714183/pubmed" id="28714183" target="_blank">28714183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9683157">
<a name="9683157"></a>Chiu AM, Chuenkongkaew WL, Cornblath WT, et al. Minocycline treatment and pseudotumor cerebri syndrome. <i>Am J Ophthalmol</i>. 1998;126(1):116-121. doi:10.1016/s0002-9394(98)00063-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9683157/pubmed" id="9683157" target="_blank">9683157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837. doi:10.2165/00128072-200204120-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29469742">
<a name="29469742"></a>Clark AK, Shi VY, Sivamani RK. Unique urticarial presentation of minocycline-induced lupus erythematosus. <i>Dermatol Online J</i>. 2017;23(8):13030/qt6w86q8v4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/29469742/pubmed" id="29469742" target="_blank">29469742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14074423">
<a name="14074423"></a>Cohlan SQ. Teratogenic agents and congenital malformations. <i>J Pediatr</i>. 1963;63:650-659. doi:10.1016/s0022-3476(63)80375-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/14074423/pubmed" id="14074423" target="_blank">14074423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CoreMino.2017.01">
<a name="CoreMino.2017.01"></a>CoreMino (minocycline hydrochloride) extended-release tablets [prescribing information]. Malvern, PA: Encore Dermatology; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CoreMino.2017.02">
<a name="CoreMino.2017.02"></a>CoreMino (minocycline hydrochloride) [prescribing information]. Malvern, PA: Encore Dermatology, Inc; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10447381">
<a name="10447381"></a>Correia O, Delgado L, Polónia J. Genital fixed drug eruption: cross-reactivity between doxycycline and minocycline. <i>Clin Exp Dermatol</i>. 1999;24(2):137. doi:10.1046/j.1365-2230.1999.00436.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10447381/pubmed" id="10447381" target="_blank">10447381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26680308">
<a name="26680308"></a>Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? <i>Expert Opin Drug Saf</i>. 2016;15(3):367-382. doi:10.1517/14740338.2016.1133584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26680308/pubmed" id="26680308" target="_blank">26680308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11168126">
<a name="11168126"></a>Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. <i>Clin Microbiol Infect.</i> 2000;6(5):270-273. doi:10.1046/j.1469-0691.2000.00058-2.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11168126/pubmed" id="11168126" target="_blank">11168126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10878205">
<a name="10878205"></a>Davey P, Lalloo DG. Drug induced chest pain-rare but important. <i>Postgrad Med J</i>. 2000;76(897):420-422. doi:10.1136/pmj.76.897.420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10878205/pubmed" id="10878205" target="_blank">10878205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2527068">
<a name="2527068"></a>Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. <i>BMJ</i>. 1989;298(6686):1523-1524. doi:10.1136/bmj.298.6686.1523-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/2527068/pubmed" id="2527068" target="_blank">2527068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12839588">
<a name="12839588"></a>Descamps V, Collot S, Mahé E, Houhou N, Crickx B, Ranger-Rogez S. Active human herpesvirus 6 infection in a patient with drug rash with eosinophilia and systemic symptoms.<i> J Invest Dermatol</i>. 2003;121(1):215-216. doi:10.1046/j.1523-1747.2003.12333.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12839588/pubmed" id="12839588" target="_blank">12839588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21155087">
<a name="21155087"></a>Dodiuk-Gad R, Cohen E, Ziv, M, et al. Cutaneous nocardiosis: report of two cases and review of the literature. <i>Int J Derm</i>. 2010; 49(12):1380-1385. doi:10.1111/j.1365-4632.2010.04554.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/21155087/pubmed" id="21155087" target="_blank">21155087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33494681">
<a name="33494681"></a>Dominic MR. Adverse reactions induced by minocycline: A review of literature. <i>Curr Drug Saf</i>. 2021;16(3):309-321. doi:10.2174/1574886316666210120090446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/33494681/pubmed" id="33494681" target="_blank">33494681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31179779">
<a name="31179779"></a>Dosik J, Ellman H, Stuart I. Topical minocycline foam 4%: Results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation. <i>J Immunotoxicol</i>. 2019;16(1):133-139. doi:10.1080/1547691X.2019.1610117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/31179779/pubmed" id="31179779" target="_blank">31179779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10735951">
<a name="10735951"></a>Dunphy J, Oliver M, Rands AL, Lovell CR, McHugh NJ. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. <i>Br J Dermatol</i>. 2000;142(3):461-467. doi:10.1046/j.1365-2133.2000.03357.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10735951/pubmed" id="10735951" target="_blank">10735951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7787604">
<a name="7787604"></a>Dykhuizen RS, Zaidi AM, Godden DJ, Jegarajah S, Legge JS. Minocycline and pulmonary eosinophilia. <i>BMJ</i>. 1995;310(6993):1520-1521. doi:10.1136/bmj.310.6993.1520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/7787604/pubmed" id="7787604" target="_blank">7787604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10555598">
<a name="10555598"></a>Eichenfield AH. Minocycline and autoimmunity. <i>Curr Opin Pediatr</i>. 1999;11(5):447-456. doi:10.1097/00008480-199910000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10555598/pubmed" id="10555598" target="_blank">10555598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131(suppl 3):S163-S186. doi:10.1542/peds.2013-0490B<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9638388">
<a name="9638388"></a>Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. <i>Drug Saf</i>. 1998;18(6):431-440. doi:10.2165/00002018-199818060-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9638388/pubmed" id="9638388" target="_blank">9638388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10406406">
<a name="10406406"></a>Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. <i>Semin Arthritis Rheum</i>. 1999;28(6):392-397. doi:10.1016/s0049-0172(99)80004-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10406406/pubmed" id="10406406" target="_blank">10406406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19153346">
<a name="19153346"></a>Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. <i>Arch Dermatol</i>. 2009;145(1):67-72. doi:10.1001/archderm.145.1.67<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/19153346/pubmed" id="19153346" target="_blank">19153346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-324400">
<a name="324400"></a>Fanning WL, Gump DW, Sofferman RA. Side effects of minocycline: a double-blind study. <i>Antimicrob Agents Chemother</i>. 1977;11(4):712-717. doi:10.1128/AAC.11.4.712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/324400/pubmed" id="324400" target="_blank">324400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13699377">
<a name="13699377"></a>Fields JP. Bulging fontanel: a complication of tetracycline therapy in infants. <i>J Pediatr</i>. 1961;58:74-76. doi:10.1016/s0022-3476(61)80061-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/13699377/pubmed" id="13699377" target="_blank">13699377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617786">
<a name="18617786"></a>Ford TJ, Dillon JF. Minocycline hepatitis. <i>Eur J Gastroenterol Hepatol</i>. 2008;20(8):796-799. doi:10.1097/MEG.0b013e3282f493c5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/18617786/pubmed" id="18617786" target="_blank">18617786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22490325">
<a name="22490325"></a>Fraser CL, Biousse V, Newman NJ. Minocycline-induced fulminant intracranial hypertension. <i>Arch Neurol</i>. 2012;69(8):1067-1070. doi:10.1001/archneurol.2012.144<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/22490325/pubmed" id="22490325" target="_blank">22490325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675888">
<a name="15675888"></a>Friedman DI. Medication-induced intracranial hypertension in dermatology. <i>Am J Clin Dermatol</i>. 2005;6(1):29-37. doi:10.2165/00128071-200506010-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/15675888/pubmed" id="15675888" target="_blank">15675888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11896769">
<a name="11896769"></a>Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. <i>Dermatol Surg</i>. 2002;28(3):205-209. doi:10.1046/j.1524-4725.2002.01083.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11896769/pubmed" id="11896769" target="_blank">11896769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5026677">
<a name="5026677"></a>Frost P, Weinstein GD, Gomez EC. Phototoxic potential of minocycline and doxycycline. <i>Arch Dermatol</i>. 1972;105(5):681-683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/5026677/pubmed" id="5026677" target="_blank">5026677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22895927">
<a name="22895927"></a>Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. <i>Cochrane Database Syst Rev</i>. 2012;2012(8):CD002086. doi:10.1002/14651858.CD002086.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/22895927/pubmed" id="22895927" target="_blank">22895927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23441623">
<a name="23441623"></a>Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic.<i> Br J Pharmacol</i>. 2013;169(2):337-352. doi:10.1111/bph.12139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23441623/pubmed" id="23441623" target="_blank">23441623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19595269">
<a name="19595269"></a>Geria AN, Tajirian AL, Kihiczak G, Schwartz RA. Minocycline-induced skin pigmentation: an update. <i>Acta Dermatovenerol Croat</i>. 2009;17(2):123-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/19595269/pubmed" id="19595269" target="_blank">19595269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12165215">
<a name="12165215"></a>Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. <i>Dermatol Online J</i>. 2002;8(1):5. http://dermatology.cdlib.org/DOJvol8num1/reviews/drugrxn/ghislain.html
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12165215/pubmed" id="12165215" target="_blank">12165215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25371514">
<a name="25371514"></a>Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. <i>Clin Infect Dis</i>. 2014;59 suppl 6:S381-S387. doi:10.1093/cid/ciu593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/25371514/pubmed" id="25371514" target="_blank">25371514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8563540">
<a name="8563540"></a>Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. <i>BMJ</i>. 1996;312(7024):169-172. doi:10.1136/bmj.312.7024.169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8563540/pubmed" id="8563540" target="_blank">8563540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12716217">
<a name="12716217"></a>Goulden V. Guidelines for the management of acne vulgaris in adolescents. <i>Paediatr Drugs</i>. 2003;5(5):301-313. doi:10.2165/00128072-200305050-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12716217/pubmed" id="12716217" target="_blank">12716217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8733373">
<a name="8733373"></a>Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. <i>Br J Dermatol</i>. 1996;134(4):693-695. doi:10.1111/j.1365-2133.1996.tb06972.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8733373/pubmed" id="8733373" target="_blank">8733373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-303498">
<a name="303498"></a>Gump DW, Ashikaga T, Fink TJ, Radin AM. Side effects of minocycline: different dosage regimens. <i>Antimicrob Agents Chemother</i>. 1977;12(5):642-646. doi:10.1128/AAC.12.5.642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/303498/pubmed" id="303498" target="_blank">303498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31382572">
<a name="31382572"></a>Hamilton LA, Guarascio AJ. Tetracycline allergy. <i>Pharmacy (Basel)</i>. 2019;7(3):104. doi:10.3390/pharmacy7030104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/31382572/pubmed" id="31382572" target="_blank">31382572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26801080">
<a name="26801080"></a>Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. <i>J Antimicrob Chemother</i>. 2016;71(4):1071-1075. doi:10.1093/jac/dkv456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26801080/pubmed" id="26801080" target="_blank">26801080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8740328">
<a name="8740328"></a>Harel L, Amir J, Livni E, Straussberg R, Varsano I. Serum-sickness-like reaction associated with minocycline therapy in adolescents. <i>Ann Pharmacother</i>. 1996;30(5):481-483. doi:10.1177/106002809603000509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8740328/pubmed" id="8740328" target="_blank">8740328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30345250">
<a name="30345250"></a>Harmon EG, McConnie R, Kesavan A. Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis.<i> Pediatr Gastroenterol Hepatol Nutr.</i> 2018;21(4):347-350. doi:10.5223/pghn.2018.21.4.347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30345250/pubmed" id="30345250" target="_blank">30345250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27870777">
<a name="27870777"></a>Haskes C, Shea M, Imondi D. Minocycline-induced scleral and dermal hyperpigmentation. <i>Optom Vis Sci</i>. 2017;94(3):436-442. doi:10.1097/OPX.0000000000001024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/27870777/pubmed" id="27870777" target="_blank">27870777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HRSA.1">
<a name="HRSA.1"></a>Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: recommended treatment regimens. Accessed March 31, 2016. <a href="https://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html" target="_blank">https://www.hrsa.gov/hansensdisease/diagnosis/recommendedtreatment.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hicks.1">
<a name="Hicks.1"></a>Hicks CB, Clement M. Syphilis: treatment and monitoring. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed February 22, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8736342">
<a name="8736342"></a>Hunt MJ, Salisbury EL, Grace J, Armati R. Black breast milk due to minocycline therapy. <i>Br J Dermatol</i>. 1996;134(5):943-944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8736342/pubmed" id="8736342" target="_blank">8736342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1081373">
<a name="1081373"></a>Jacobson JA, Daniel B. Vestibular reactions associated with minocycline. <i>Antimicrob Agents Chemother.</i> 1975;8(4):453-456. doi:10.1128/AAC.8.4.453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1081373/pubmed" id="1081373" target="_blank">1081373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516472">
<a name="27516472"></a>Jacobson S, Junco Noa L, Wallace MR, Bowman MC. Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. <i>J Antimicrob Chemother</i>. 2016;71(12):3620. doi:10.1093/jac/dkw327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/27516472/pubmed" id="27516472" target="_blank">27516472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20676339">
<a name="20676339"></a>Jang JW, Bae YJ, Kim YG, et al. A case of anaphylaxis to oral minocycline. <i>J Korean Med Sci</i>. 2010;25(8):1231-1233. doi:10.3346/jkms.2010.25.8.1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/20676339/pubmed" id="20676339" target="_blank">20676339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23887527">
<a name="23887527"></a>Johnston S. Feeling blue? Minocycline-induced staining of the teeth, oral mucosa, sclerae and ears - a case report. <i>Br Dent J</i>. 2013;215(2):71-73. doi:10.1038/sj.bdj.2013.682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23887527/pubmed" id="23887527" target="_blank">23887527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23158645">
<a name="23158645"></a>Kalai C, Brand R, Yu L. Minocycline-induced Sweet syndrome (acute febrile neutrophilic dermatosis). <i>J Am Acad Dermatol</i>. 2012;67(6):e289-91. doi:10.1016/j.jaad.2012.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23158645/pubmed" id="23158645" target="_blank">23158645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21113440">
<a name="21113440"></a>Kandil E, Abdel Khalek M, Alabbas H, et al. Black thyroid associated with thyroid carcinoma. <i>Int J Endocrinol</i>. 2010;2010:681647. doi:10.1155/2010/681647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/21113440/pubmed" id="21113440" target="_blank">21113440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24471460">
<a name="24471460"></a>Kanno K, Sakai H, Yamada Y, Iizuka H. Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis. <i>J Dermatol</i>. 2014;41(2):160-162. doi:10.1111/1346-8138.12378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24471460/pubmed" id="24471460" target="_blank">24471460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34919357">
<a name="34919357"></a>Katayama S, Ota M. Minocycline-induced hyperpigmentation. <i>N Engl J Med</i>. 2021;385(26):2463. doi:10.1056/NEJMicm2111130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34919357/pubmed" id="34919357" target="_blank">34919357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22704357">
<a name="22704357"></a>Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. <i>Semin Arthritis Rheum</i>. 2012;42(2):213-221. doi:10.1016/j.semarthrit.2012.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/22704357/pubmed" id="22704357" target="_blank">22704357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6455257">
<a name="6455257"></a>Kestel JL Jr. Photo-onycholysis from minocycline. Side effects of minocycline therapy. <i>Cutis</i>. 1981;28(1):53-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/6455257/pubmed" id="6455257" target="_blank">6455257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12207601">
<a name="12207601"></a>Khan Durani B, Jappe U. Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. <i>Br J Dermatol</i>. 2002;147(3):558-562. doi:10.1046/j.1365-2133.2002.04817.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12207601/pubmed" id="12207601" target="_blank">12207601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32551128">
<a name="32551128"></a>Khanna S, Tarafdar S. Minocycline-induced Sweet's syndrome. <i>Oxf Med Case Reports</i>. 2020;2020(6):omaa037. doi:10.1093/omcr/omaa037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/32551128/pubmed" id="32551128" target="_blank">32551128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8185689">
<a name="8185689"></a>Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. <i>Arthritis Rheum</i>. 1994;37(5):629-636. doi:10.1002/art.1780370505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8185689/pubmed" id="8185689" target="_blank">8185689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8849255">
<a name="8849255"></a>Kloppenburg M, Brinkman BM, de Rooij-Dijk HH,et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. <i>Antimicrob Agents Chemother</i>. 1996;40(4):934-940. doi:10.1128/AAC.40.4.934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8849255/pubmed" id="8849255" target="_blank">8849255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8712844">
<a name="8712844"></a>Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. <i>Arch Dermatol</i>. 1996;132(8):934-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8712844/pubmed" id="8712844" target="_blank">8712844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23657872">
<a name="23657872"></a>Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787. doi:10.1007/s40265-013-0060-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23657872/pubmed" id="23657872" target="_blank">23657872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26782675">
<a name="26782675"></a>Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. <i>Ann Allergy Asthma Immunol</i>. 2016;116(4):367-368. doi:10.1016/j.anai.2015.12.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26782675/pubmed" id="26782675" target="_blank">26782675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10877258">
<a name="10877258"></a>Landau M, Shachar E, Brenner S. Minocycline-induced serum sickness-like reaction.<i> J Eur Acad Dermatol Venereol</i>. 2000;14(1):67-68. doi:10.1046/j.1468-3083.2000.00007-3.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10877258/pubmed" id="10877258" target="_blank">10877258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28357705">
<a name="28357705"></a>Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review.<i> Infect Dis Ther.</i> 2017;6(2):199-211. doi:10.1007/s40121-017-0153-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/28357705/pubmed" id="28357705" target="_blank">28357705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34794979">
<a name="34794979"></a>Law S. Minocycline-induced blue sclera and skin hyperpigmentation. <i>BMJ Case Rep</i>. 2021;14(11):e245508. doi:10.1136/bcr-2021-245508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34794979/pubmed" id="34794979" target="_blank">34794979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11051220">
<a name="11051220"></a>Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. <i>Drug Saf</i>. 2000;23(4):333-349. doi:10.2165/00002018-200023040-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11051220/pubmed" id="11051220" target="_blank">11051220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11285382">
<a name="11285382"></a>Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. <i>Rheumatology (Oxford)</i>. 2001;40(3):329-335. doi:10.1093/rheumatology/40.3.329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11285382/pubmed" id="11285382" target="_blank">11285382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22283782">
<a name="22283782"></a>Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O; French Network of Regional Centers of Pharmacovigilance. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. <i>Br J Dermatol</i>. 2012;166(6):1333-1341. doi:10.1111/j.1365-2133.2012.10845.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/22283782/pubmed" id="22283782" target="_blank">22283782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17511865">
<a name="17511865"></a>Lefebvre N, Forestier E, Farhi D, et al. Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report. <i>J Med Case Rep</i>. 2007;1:22. doi:10.1186/1752-1947-1-22<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/17511865/pubmed" id="17511865" target="_blank">17511865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23604593">
<a name="23604593"></a>Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. <i>Clin Rheumatol</i>. 2013;32(7):1099-1106. doi:10.1007/s10067-013-2245-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23604593/pubmed" id="23604593" target="_blank">23604593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783685">
<a name="8783685"></a>Lerner PI. Nocardiosis. <i>Clin Infect Dis</i>. 1996;22(6):891-903; quiz 904-5. doi:10.1093/clinids/22.6.891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8783685/pubmed" id="8783685" target="_blank">8783685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. <i>Clin Infect Dis</i>. 2011;52(3):285-292. doi:10.1093/cid/cir034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775664">
<a name="30775664"></a>Loner CA, Crane PW. Use of emergency department extracorporeal membrane oxygenation for treatment of acute necrotizing myocarditis. <i>Clin Pract Cases Emerg Med</i>. 2019;3(1):47-50. doi:10.5811/cpcem.2018.11.40569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30775664/pubmed" id="30775664" target="_blank">30775664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34449992">
<a name="34449992"></a>Lucido CT, Johnson J. Serum sickness-like reaction in an adolescent taking minocycline for acne. <i>S D Med</i>. 2021;74(7):310-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34449992/pubmed" id="34449992" target="_blank">34449992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2501265">
<a name="2501265"></a>Maesen FP, Davies BI, van den Bergh JJ. Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. <i>J Antimicrob Chemother.</i> 1989;23(1):123-129. doi:10.1093/jac/23.1.123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/2501265/pubmed" id="2501265" target="_blank">2501265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33418019">
<a name="33418019"></a>Margalit I, Lebeaux D, Tishler O, et al. How do I manage nocardiosis? <i>Clin Microbiol Infect</i>. 2021;27(4):550-558. doi:10.1016/j.cmi.2020.12.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/33418019/pubmed" id="33418019" target="_blank">33418019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34206485">
<a name="34206485"></a>Martins AM, Marto JM, Johnson JL, Graber EM. A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea. <i>Antibiotics (Basel)</i>. 2021;10(7):757. doi:10.3390/antibiotics10070757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34206485/pubmed" id="34206485" target="_blank">34206485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182810">
<a name="18182810"></a>Maubec E, Wolkenstein P, Loriot MA, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. <i>Dermatology</i>. 2008;216(3):200-204. doi:10.1159/000112926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/18182810/pubmed" id="18182810" target="_blank">18182810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30933349">
<a name="30933349"></a>McCarthy S, Bourke JF. Image Gallery: Minocycline-induced photo-onycholysis with pigmentation. <i>Br J Dermatol</i>. 2019;180(4):e102. doi:10.1111/bjd.17417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30933349/pubmed" id="30933349" target="_blank">30933349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McNamara.1">
<a name="McNamara.1"></a>McNamara LA, Blain A. Centers for Disease Control and Prevention Manual for the Surveillance of Vaccine-Preventable Disease. <a href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html" target="_blank">https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html</a>. Accessed September 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi:10.3201/eid2002.130611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31533103">
<a name="31533103"></a>Millington K, Charrow A, Smith J. Case series: Minocycline-associated thyroiditis. <i>Horm Res Paediatr</i>. 2019;92(4):276-283. doi:10.1159/000502843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/31533103/pubmed" id="31533103" target="_blank">31533103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1532250">
<a name="1532250"></a>Min DI, Burke PA, Lewis WD, Jenkins RL. Acute hepatic failure associated with oral minocycline: a case report. <i>Pharmacotherapy</i>. 1992;12(1):68-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1532250/pubmed" id="1532250" target="_blank">1532250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocin.2021.02">
<a name="Minocin.2021.02"></a>Minocin (minocycline) injection [prescribing information]. Lincolnshire, IL: Melinta Therapeutics LLC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocin.2018.11">
<a name="Minocin.2018.11"></a>Minocin (minocycline) oral suspension [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocin.2019.01">
<a name="Minocin.2019.01"></a>Minocin (minocycline) pellet-filled capsules [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocycline.2018.12">
<a name="Minocycline.2018.12"></a>Minocycline capsules [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocycline.2019.01">
<a name="Minocycline.2019.01"></a>Minocycline capsules [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MinocyclineER.2018.12">
<a name="MinocyclineER.2018.12"></a>Minocycline extended-release tablets [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocyclinefilm.2018.05">
<a name="Minocyclinefilm.2018.05"></a>Minocycline film-coated tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MinocyclineHCl.2015.07">
<a name="MinocyclineHCl.2015.07"></a>Minocycline hydrochloride [prescribing information]. Basking Ridge, NJ: Torrent Pharma; July 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MinocyclineHCl.2018.01">
<a name="MinocyclineHCl.2018.01"></a>Minocycline hydrochloride capsules [prescribing information]. Basking Ridge, NJ: Torrent Pharma Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocyclinetabs.2018.05">
<a name="Minocyclinetabs.2018.05"></a>Minocycline hydrochloride tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocyclineinj.2018.05">
<a name="Minocyclineinj.2018.05"></a>Minocycline hydrochloride injection [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minocyclinesusp.2018.11">
<a name="Minocyclinesusp.2018.11"></a>Minocycline oral suspension [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minolira.2018.06">
<a name="Minolira.2018.06"></a>Minolira (minocycline) extended-released tablets [prescribing information]. Charleston, SC: EPI Health, LLC; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minolira.2017.05">
<a name="Minolira.2017.05"></a>Minolira (minocycline) extended-released tablets [prescribing information]. Princeton, NJ: Promius Pharma LLC; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3755739">
<a name="3755739"></a>Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. <i>J Invest Dermatol</i>. 1986;86(4):449-453. doi:10.1111/1523-1747.ep12285793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/3755739/pubmed" id="3755739" target="_blank">3755739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30402608">
<a name="30402608"></a>Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. <i>Allergol Select</i>. 2017;1(1):96-108. doi:10.5414/ALX01508E<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30402608/pubmed" id="30402608" target="_blank">30402608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814687">
<a name="20814687"></a>Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. <i>Arch Gynecol Obstet</i>. 2011;283(1):7-18. doi:10.1007/s00404-010-1646-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/20814687/pubmed" id="20814687" target="_blank">20814687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12796202">
<a name="12796202"></a>Oddo M, Liaudet L, Lepori M, Broccard AF, Schaller MD. Relapsing acute respiratory failure induced by minocycline. <i>Chest</i>. 2003;123(6):2146-2148. doi:10.1378/chest.123.6.2146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12796202/pubmed" id="12796202" target="_blank">12796202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9153544">
<a name="9153544"></a>O’Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum</i>. 1997;40(5):842-848. doi:10.1002/art.1780400510<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9153544/pubmed" id="9153544" target="_blank">9153544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11665963">
<a name="11665963"></a>O’Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. <i>Arthritis Rheum</i>. 2001;44(10):2235-2241. doi:10.1002/1529-0131(200110)44:10&lt;2235::aid-art385&gt;3.0.co;2-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11665963/pubmed" id="11665963" target="_blank">11665963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33991382">
<a name="33991382"></a>Odorici G, Monfrecola G, Bettoli V. Tetracyclines and photosensitive skin reactions: A narrative review. <i>Dermatol Ther</i>. 2021;34(4):e14978. doi:10.1111/dth.14978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/33991382/pubmed" id="33991382" target="_blank">33991382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8740283">
<a name="8740283"></a>Okano M, Imai S. Anaphylactoid symptoms due to oral minocycline. <i>Acta Derm Venereol</i>. 1996;76(2):164. doi:10.2340/0001555576164164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8740283/pubmed" id="8740283" target="_blank">8740283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2013;56(1):e1-e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11680122">
<a name="11680122"></a>Oswald J, Meier K, Reinhart WH, Kuhn M. Pseudotumor cerebri unter Minocyclin [Pseudotumor cerebri in minocyline treatment]. <i>Praxis (Bern 1994)</i>. 2001;90(39):1691-1693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11680122/pubmed" id="11680122" target="_blank">11680122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12948923">
<a name="12948923"></a>Pelletier F, Puzenat E, Blanc D, Faivre B, Humbert P, Aubin F. Minocycline-induced cutaneous polyarteritis nodosa with antineutrophil cytoplasmic antibodies. <i>Eur J Dermatol</i>. 2003;13(4):396-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/12948923/pubmed" id="12948923" target="_blank">12948923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8436641">
<a name="8436641"></a>Pepine M, Flowers FP, Ramos-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. <i>J Am Acad Dermatol</i>. 1993;28(2 Pt 2):292-295. doi:10.1016/0190-9622(93)70037-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8436641/pubmed" id="8436641" target="_blank">8436641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6345836">
<a name="6345836"></a>Petersen EA, Nash ML, Mammana RB, Copeland JG. Minocycline treatment of pulmonary nocardiosis. <i>JAMA</i>.1983:250(7):930-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/6345836/pubmed" id="6345836" target="_blank">6345836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25371515">
<a name="25371515"></a>Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. <i>Clin Infect Dis</i>. 2014;59(suppl 6):S388-S393. doi:10.1093/cid/ciu594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/25371515/pubmed" id="25371515" target="_blank">25371515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730650">
<a name="32730650"></a>Prejean R, Haas C. Recalcitrant minocycline-induced DRESS mimicking HLH. <i>Dermatol Ther</i>. 2020;33(6):e14104. doi:10.1111/dth.14104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/32730650/pubmed" id="32730650" target="_blank">32730650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1417938">
<a name="1417938"></a>Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. <i>Biochem Pharmacol</i>. 1992;44(6):1165-1170. doi:10.1016/0006-2952(92)90381-r<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1417938/pubmed" id="1417938" target="_blank">1417938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23914887">
<a name="23914887"></a>Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311. doi:10.1111/dth.12077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/23914887/pubmed" id="23914887" target="_blank">23914887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35160164">
<a name="35160164"></a>Radovanovic M, Jevtic D, Calvin AD, et al. "Heart in DRESS": Cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: A systematic review. <i>J Clin Med</i>. 2022;11(3):704. doi:10.3390/jcm11030704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/35160164/pubmed" id="35160164" target="_blank">35160164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817024">
<a name="30817024"></a>Restrepo A, Clark NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Nocardia infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. <i>Clin Transplant</i>. 2019;33(9):e13509. doi:10.1111/ctr.13509<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30817024/pubmed" id="30817024" target="_blank">30817024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25371513">
<a name="25371513"></a>Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. <i>Clin Infect Dis</i>. 2014;59 suppl 6:S374-S380. doi:10.1093/cid/ciu613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/25371513/pubmed" id="25371513" target="_blank">25371513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33916535">
<a name="33916535"></a>Rok J, Rzepka Z, Kowalska J, Banach K, Beberok A, Wrześniok D. Molecular and biochemical basis of minocycline-induced hyperpigmentation-The study on normal human melanocytes exposed to UVA and UVB radiation.<i> Int J Mol Sci</i>. 2021;22(7):3755. doi:10.3390/ijms22073755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/33916535/pubmed" id="33916535" target="_blank">33916535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3072140">
<a name="3072140"></a>Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. <i>Clin Pharmacokinet</i>. 1988;15(6):355-366. doi:10.2165/00003088-198815060-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/3072140/pubmed" id="3072140" target="_blank">3072140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11504273">
<a name="11504273"></a>Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD. The risk of liver damage associated with minocycline: a comparative study. <i>J Clin Pharmacol</i>. 2001;41(8):852-860. doi:10.1177/00912700122010753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/11504273/pubmed" id="11504273" target="_blank">11504273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30186098">
<a name="30186098"></a>Shah J, Shahidullah A, Liu Y. Drug-induced autoimmune hepatitis in a patient treated with minocycline: a rare adverse effect. <i>Case Rep Gastroenterol</i>. 2018;12(2):447-452. doi:10.1159/000492214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30186098/pubmed" id="30186098" target="_blank">30186098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28033297">
<a name="28033297"></a>Shao LL, Guo R, Shi WJ, et al. Could lengthening minocycline therapy better treat early syphilis? <i>Medicine (Baltimore)</i>. 2016;95(52):e5773. doi:10.1097/MD.0000000000005773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/28033297/pubmed" id="28033297" target="_blank">28033297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9382560">
<a name="9382560"></a>Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. <i>Arch Dermatol</i>. 1997;133(10):1224-1230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9382560/pubmed" id="9382560" target="_blank">9382560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32742656">
<a name="32742656"></a>Sharma K, Geagan N, Tengsupakul S. Severe acute interstitial nephritis secondary to minocycline use in an adolescent girl. <i>SAGE Open Med Case Rep</i>. 2020;8:2050313X20943069. doi:10.1177/2050313X20943069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/32742656/pubmed" id="32742656" target="_blank">32742656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19665822">
<a name="19665822"></a>Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis.<i> J Am Acad Dermatol</i>. 2010;62(2):315-308. doi:10.1016/j.jaad.2009.05.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/19665822/pubmed" id="19665822" target="_blank">19665822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32839167">
<a name="32839167"></a>Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. <i>CMAJ</i>. 2020;192(34):E981. doi:10.1503/cmaj.200012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/32839167/pubmed" id="32839167" target="_blank">32839167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545825">
<a name="26545825"></a>Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2016;68(1):1-25. doi:10.1002/acr.22783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26545825/pubmed" id="26545825" target="_blank">26545825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8031212">
<a name="8031212"></a>Sitbon O, Bidel N, Dussopt C, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. <i>Arch Intern Med</i>. 1994;154(14):1633-1640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/8031212/pubmed" id="8031212" target="_blank">8031212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1749296">
<a name="1749296"></a>Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. <i>Mayo Clin Proc</i>. 1991;66(12):1270-1280. doi:10.1016/s0025-6196(12)62479-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1749296/pubmed" id="1749296" target="_blank">1749296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solodyn.2017.09">
<a name="Solodyn.2017.09"></a>Solodyn (minocycline) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.1">
<a name="Spelman.1"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed June 17, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com.</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34348742">
<a name="34348742"></a>Steadman W, Brown Z, Wall CJ. Minocycline black bone disease in arthroplasty: a systematic review. <i>J Orthop Surg Res</i>. 2021;16(1):479. doi:10.1186/s13018-021-02617-w. Erratum in: <i>J Orthop Surg Res</i>. 2022;17(1):295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34348742/pubmed" id="34348742" target="_blank">34348742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14528503">
<a name="14528503"></a>Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. <i>J Rheumatol</i>. 2003;30(10):2112-2122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/14528503/pubmed" id="14528503" target="_blank">14528503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed March 17, 2022. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17276540">
<a name="17276540"></a>Strauss JS, Krowchuk DP, Leyden JJ, et al; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. <i>J Am Acad Dermatol</i>. 2007;56(4):651-663. doi:10.1016/j.jaad.2006.08.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/17276540/pubmed" id="17276540" target="_blank">17276540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10074958">
<a name="10074958"></a>Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. <i>Arch Intern Med</i>. 1999;159(5):493-497. doi:10.1001/archinte.159.5.493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/10074958/pubmed" id="10074958" target="_blank">10074958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tamma.1">
<a name="Tamma.1"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant <i>Acinetobacter baumannii</i>, and <i>Stenotrophomonas maltophilia</i> Infections. Infectious Diseases Society of America 2022; Version 2.0. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/. Accessed September 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: A systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397059">
<a name="30397059"></a>Tarazi Z, Sabet M, Dudley MN, Griffith DC. Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model. <i>Antimicrob Agents Chemother.</i> 2019;63(2):e01671-18. doi:10.1128/AAC.01671-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30397059/pubmed" id="30397059" target="_blank">30397059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Threlkeld.1997">
<a name="Threlkeld.1997"></a>Threlkeld SC, Hooper DC. Update on Management of Patients with <i>Nocardia</i> Infection. Current Clinical Topics in Infectious Diseases. Remington JS, Swartz MN, eds. Malden: Blackwell Science, 1997. 1-23.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7993000">
<a name="7993000"></a>Tilley BC, Alarcón GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. <i>Ann Intern Med</i>. 1995;122(2):81-89. doi:10.7326/0003-4819-122-2-199501150-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/7993000/pubmed" id="7993000" target="_blank">7993000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9778198">
<a name="9778198"></a>Vassileva SG, Mateev G, Parish LC. Antimicrobial photosensitive reactions. <i>Arch Intern Med</i>. 1998;158(18):1993-2000. doi:10.1001/archinte.158.18.1993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9778198/pubmed" id="9778198" target="_blank">9778198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1211910">
<a name="1211910"></a>Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA. Pharmacokinetics of minocycline in renal failure. <i>Antimicrob Agents Chemother</i>. 1975;8(5):532-537. doi:10.1128/AAC.8.5.532<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/1211910/pubmed" id="1211910" target="_blank">1211910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9029456">
<a name="9029456"></a>Westbury LW, Najera A. Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. <i>J Periodontol</i>. 1997;68(1):84-91. doi:10.1902/jop.1997.68.1.84<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/9029456/pubmed" id="9029456" target="_blank">9029456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at: www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442509">
<a name="30442509"></a>Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? <i>Diagn Microbiol Infect Dis</i>. 2019;93(3):238-242. doi:10.1016/j.diagmicrobio.2018.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/30442509/pubmed" id="30442509" target="_blank">30442509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33496202">
<a name="33496202"></a>Wu H, Qi M, Wang H, Liu Q, Liu Y. Efficacy of minocycline in the treatment of early syphilis. <i>Int J STD AIDS</i>. 2021;32(7):648-653. doi:10.1177/0956462420984695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/33496202/pubmed" id="33496202" target="_blank">33496202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ximino.2019.11">
<a name="Ximino.2019.11"></a>Ximino (minocycline) [prescribing information]. New Brunswick, NJ: Ohm Laboratories Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ximino.2015.08">
<a name="Ximino.2015.08"></a>Ximino (minocycline) [prescribing information]. Jacksonville, FL: Ranbaxy Labs; August 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21103193">
<a name="21103193"></a>Yoon J, Lee SH, Kim TH, Choi DJ, Kim JP, Yoon TJ. Concurrence of Stevens-Johnson syndrome and bilateral parotitis after minocycline therapy. <i>Case Rep Dermatol</i>. 2010;2(2):88-94. doi:10.1159/000314952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/21103193/pubmed" id="21103193" target="_blank">21103193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14723559">
<a name="14723559"></a>Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. <i>Drugs</i>. 2004;64(1):63-88. doi:10.2165/00003495-200464010-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/minocycline-systemic-pediatric-drug-information/abstract-text/14723559/pubmed" id="14723559" target="_blank">14723559</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 122967 Version 219.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
